Adverse Events of Bedaquiline Drug Use in the Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) Patients: A Review Artcile
Abstract
Adverse Drug Reaction (ADR) is any unfavorable and unexpected drug response in patients dosed for prevention, diagnosis, or therapy. Tuberculosis is a contagious infectious disease caused by the bacterium Mycobacterium tuberculosis. Multi-drug resistance Tuberculosis (MDR TB) is caused by bacteria that are resistant to the two most powerful first-line anti-TB drugs - isoniazid and rifampicin; cases of resistance to both drugs result in worse treatment outcomes, longer treatment duration, high costs, and various other complications. All medications used to treat MDR TB patients have the potential to cause mild, moderate, and severe side effects, especially Bedaquiline. This article will explain information on drug side effects that occur in patients treated with MDR TB and Bedaquiline. The data was collected and discussed from primary journals through Google Scholar and PubMed online databases. Bedaquiline has the potential to cause side effects such as QT interval prolongation or irregular heart rhythm, cardiac arrhythmia, gastrointestinal disorders, joint and muscle pain, hearing loss, acne, and chest pain. Therefore, treatment of MDR TB with Bedaquiline requires monitoring to ensure patient compliance and early detection of possible side effects to ensure the safety and effectiveness of treatment.
Keywords
Full Text:
PDFReferences
References
Khalil H, Huang C. Adverse drug reactions in primary care: a scoping review. BMC Health Serv Res. 2020;20(1):5. doi:10.1186/s12913-019-4651-7
Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med (Northfield Il). 2016;16(5):481–485. doi:10.7861/clinmedicine.16-5-481
Nita Y, Subakti B, Zairina E. Pengetahuan dan Sikap Tenaga Kesehatan Terhadap Pelaporan dan Monitoring Efek Samping Obat di Rumah Sakit. Published online 2005:3–7.
Kemenkes RI. Peraturan Menteri Kesehatan Republik Indonesia Nomor 72 Tahun 2016 Tentang Standar Pelayanan Kefarmasian Rumah Sakit. Published online 2016.
BPOM RI. Buletin Berita MESO. In: Vol 40. ; 2022.
BPOM RI. Buletin Berita MESO. In: Vol 41. ; 2023.
Atif M, Ahmed W, Nouman Iqbal M, et al. Frequency and Factors Associated With Adverse Events Among Multi-Drug Resistant Tuberculosis Patients in Pakistan: A Retrospective Study. Front Med. 2022;8(March):1–11. doi:10.3389/fmed.2021.790718
Koirala S, Shah NP, Pyakurel P, et al. High success and low recurrence with shorter treatment regimen for multidrug-resistant TB in Nepal. Public Heal Action. 2021;11(1):38–45. doi:10.5588/pha.21.0041
Lotia Farrukh I, Lachenal N, Adenov MM, et al. Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs. Clin Infect Dis. Published online 2023:1–5. doi:10.1093/cid/ciad445
Huerga H, Khan U, Bastard M, et al. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs. Clin Infect Dis. 2022;75(8):1307–1314. doi:10.1093/cid/ciac176
Gao JT, Du J, Wu GH, et al. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety. Infect Dis Poverty. 2021;10(1):1–10. doi:10.1186/s40249-021-00819-2
Avong YK, Isaakidis P, Hinderaker SG, et al. Doing no harm? Adverse events in a nation-wide cohort of patients with multidrug-resistant tuberculosis in Nigeria. PLoS One. 2015;10(3):1–15. doi:10.1371/journal.pone.0120161
Achalu DL, Mohammed FG, Teferi M. Magnitude and Impacts of Adverse Events of Injectable Containing Shorter Regimen in Programmatic Management of Multi-Drug Resistant Tuberculosis in Ethiopia: A Retrospective Cohort Study. Ther Clin Risk Manag. 2023;19(November):889–901. doi:10.2147/TCRM.S423163
Russom M, Tesfaselassie H, Goitom R, et al. Risk Factors of Gout in MDR-TB Patients in Eritrea: A Case-Control Study. Tuberc Res Treat. 2019;2019:1–6. doi:10.1155/2019/9429213
Khan U, Huerga H, Khan AJ, et al. The endTB observational study protocol: Treatment of MDR-TB with bedaquiline or delamanid containing regimens. BMC Infect Dis. 2019;19(1):1–9. doi:10.1186/s12879-019-4378-4
Kelly, AM; Smith B. Discordance between patient and clinician report of MDR-TB adverse drug reaction. Int J Tuberc Lung Dis. 2016;20(4):442–447. doi:10.5588/ijtld.15.0318.Discordance
Lachenal N, Hewison C, Mitnick C, et al. Setting up pharmacovigilance based on available endTB Project data for bedaquiline. Int J Tuberc Lung Dis. 2020;24(10):1087–1094. doi:10.5588/IJTLD.20.0115
Koirala S, Borisov S, Danila E, et al. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. Pulmonology. 2021;27(5):403–412. doi:10.1016/j.pulmoe.2021.02.006
Ngoc NB, Dinh HV, Thuy NT, et al. Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam. PLoS One. 2021;16(9 September):1–13. doi:10.1371/journal.pone.0255357
van der Walt M, Masuku S, Botha S, Nkwenika T, Keddy KH. Retrospective record review of pregnant women treated for rifampicin-resistant tuberculosis in South Africa. PLoS One. 2020;15(9 September):1–9. doi:10.1371/journal.pone.0239018
Tesfamariam S, Ghebrenegus AS, Woldu H, Fisseha E, Belai G, Russom M. Secondary erythrocytosis following drugs used in rifampicin/multidrug-resistant tuberculosis: A retrospective cohort study. BMJ Open Respir Res. 2021;8(1):1–7. doi:10.1136/bmjresp-2021-001064
Hewison C, Khan U, Bastard M, et al. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort. Clin Infect Dis. 2022;75(6):1006–1013. doi:10.1093/cid/ciac019
Ulfah S, Ristiono H, Perwitasari DA. Pengetahuan Dan Persepsi Apoteker Terhadap Sistem Pelaporan Monitoring Efek Samping Obat (Meso) Di Apotek Wilayah Kota Yogyakarta. J Ilm Manuntung. 2018;3(2):150–157. doi:10.51352/jim.v3i2.121
Kemenkes RI. Petunjuk Teknis Standar Pelayanan Kefarmasian Rumah Sakit.; 2019.
BPOM RI. Modul Farmakovigilans: Dasar Project For Ensuring Drug And Food Safety. Japan Int Coop Agency. Published online 2020.
Wulandari N, Andrajati R, Supardi S. Faktor Risiko Umur Lansia terhadap Kejadian Reaksi Obat yang Tidak Dikehendaki pada Pasien Hipertensi, Diabetes, Dislipidemia di Tiga Puskesmas di Kota Depok. J Kefarmasian Indones. 2016;6(1):60–67. doi:10.22435/jki.v6i1.5470.60-67
Subairi M, Muhith A, Zahro C. Multidrug Resistant Tuberculosis ( MDR-TB ) Factors : Literature Review. 2023;5(2):233–244.
Kemenkes RI. Tatalaksana Tuberkulosis.; 2020.
Yana IGAAK, Herawati F. Efektivitas Dan Keamanan Terapi dengan Rejimen Bedaquiline dalam Terapi Multidrug-Resistant Tuberculosis (TB-MDR): Kajian Sistematis. Pharm J Indones. 2022;7(2):129–138. doi:10.21776/ub.pji.2022.007.02.8
Kemenkes RI. Petunjuk Teknis Penatalaksanaan Tuberkulosis Resisten Obat di Indonesia.; 2020.
Chowdhury K, Ahmad R, Sinha S, Dutta S, Haque M. Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now. Cureus. 2023;15(2):1–15. doi:10.7759/cureus.35154
Khoshnood S, Goudarzi M, Taki E, et al. Bedaquiline: Current status and future perspectives. J Glob Antimicrob Resist. 2021;25:48–59. doi:10.1016/j.jgar.2021.02.017
Chahine EB, Karaoui LR, Mansour H. Bedaquiline: A Novel Diarylquinoline for Multidrug-Resistant Tuberculosis. Ann Pharmacother. 2014;48(1):107–115. doi:10.1177/1060028013504087
Guglielmetti L, Hewison C, Avaliani Z, et al. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. Int J Tuberc Lung Dis. 2017;21(2):167–174. doi:10.5588/ijtld.16.0493
Svensson EM, Dosne AG, Karlsson MO. Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients with Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin. CPT Pharmacometrics Syst Pharmacol. 2016;5(12):682–691. doi:10.1002/psp4.12147
Van Heeswijk RPG, Dannemann B, Hoetelmans RMW. Bedaquiline: A review of human pharmacokinetics and drug-drug interactions. J Antimicrob Chemother. 2014;69(9):2310–2318. doi:10.1093/jac/dku171
DOI: https://doi.org/10.15416/pcpr.v9i1.52762
Refbacks
- There are currently no refbacks.
